During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60246-elekta-sets-new-benchmark-for-cancer-treatment-launch-of-versa-hd-system
The Crohn’s & Colitis Foundation of America (CCFA) is collaborating with the University of North Carolina School of Medicine (UNC) to create a research partnership between patients with inflammatory bowel disease (IBD) and the scientific community. CCFA Partners is a “patient-powered research network” for Crohn’s disease and ulcerative colitis (collectively known as IBD) that uses state-of-the-art bioinformatics to engage and gather information from patients that researchers can study and analyze along with clinical and other patient-generated data.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7449851-crohn-s-colitis-foundation-ccfa-ibd/
During the month of November, VPI, a Nationwide company, will donate $5 to the Animal Cancer Foundation (ACF), up to $10,000, for every photo, story or statistic shared on Facebook, Twitter, and Instagram using #CurePetCancer. For more information, visit www.curepetcancer.com. To date, VPI has raised nearly $200,000 to benefit the ACF.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7361751-veterinary-pet-insurance-teams-with-animal-cancer-foundation-for-national-pet-cancer-awareness-month/
Patients and scientists from across the country are featured in the latest “From Hope to Cures” ad campaign launched today by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading biopharmaceutical researchers and biotechnology companies.
This continuation of PhRMA’s “From Hope to Cures” campaign, first launched in January 2014, highlights the value biopharmaceutical innovation provides to patients, society and the economy. The latest ad campaign, featuring print, radio and digital advertising, highlights the stories of patients who benefit from the medicines developed by biopharmaceutical companies and the scientists who work every day to develop life-saving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350552-phrma-from-hope-to-cures/
Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
Every spring, allergies take control of the lives of millions of Americans, affecting their work, their family time and even how well they sleep at night. Something else affects those millions of allergy sufferers, according to a new survey: big misconceptions about allergies that may keep people from getting needed relief.
To help put those misconceptions about allergies to rest, Sanofi is teaming up with science educator and television personality Adam Savage, along with allergist Dr. Neeta Ogden, to dispel them with credible information. The goal: help the 50 million allergy sufferers in America get the facts they need to understand and treat their allergies and take back control of their lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8255452-sanofi-allergy-misconceptions-facts-adam-savage/
New data from a school asthma management program, “Building Bridges for Asthma Care,” presented today at the American Thoracic Society 2015 International Conference, show a significant decrease in school absenteeism among children with asthma from inner-city schools who were enrolled in the program. Absences dropped 11.75 percent among children enrolled in Building Bridges, compared to an increase of 8.48 percent in children with asthma not in the program.
“Building Bridges for Asthma Care” is a school-based program designed to empower nurses in participating elementary schools to ensure that asthmatic children are identified and provided care according to the National Institute of Health’s clinical treatment guidelines. The objectives of the program are addressing the risk of health disparities and asthma-related absenteeism, as well as its related impact on academic achievement for inner city students.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7506851-gsk-building-bridges-for-asthma-care/
Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
Coco’s Nightclub, Miami, Florida. Great food, happening music and the best drinks makes Coco’s Nightclub. Open from noon daily to the wee-hours of the morning, anytime is a great time for you to receive the VIP treatment.
http://CocosNiteclubMiami.com
Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay™ picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
